Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baf250A, Brd9 and Baf180 knockdown impact on myoblast transcriptome

ABSTRACT: Baf250A, Brd9 and Baf180 knockdown impact on myoblast transcriptome

PROVIDER: PRJNA756240 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15526384.fastq.gz	Fastqsanger.gz
	SRR15526385.fastq.gz	Fastqsanger.gz
	SRR15526386.fastq.gz	Fastqsanger.gz
	SRR15526387.fastq.gz	Fastqsanger.gz
	SRR15526388.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Baf250A, Brd9 and Baf180 knockdown impact on myoblast transcriptome

Project description:We performed RNA-seq to investigate global changes in gene expression in proliferating myoblasts transduced with either the scramble, Baf250A, Brd9 or Baf180 shRNAs. This study revelaed that the Baf250-containing BAF complex and the Brd9-containing ncBAF complex contribute to myoblast proliferation but the Baf180-containing PBAF subfamily does not.

2022-03-04 | GSE182421 | GEO

Genome-wde mapping of BRD9 binding sites and gene expression changes upon BRD9 knockdown

Project description:Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer cells, which are unable to differentiate. While genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Here, we identify bromodomain-containing protein 9 (BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells including ex vivo primary blasts compared to CD34+ cells. By targeting BRD9 expression in AML, we observed an alteration in proliferation and survival, ultimately resulting in the induction of apoptosis. Intriguingly, genome-wide profiling revealed that BRD9 binds enhancer regions in a cell type-specific manner, regulating cell type-related processes. We unveil a novel BRD9-sustained STAT5 pathway activation via regulation of SOCS3 expression levels. Our findings identify a previously undescribed BRD9-STAT5 axis as critical for leukemia maintenance, suggesting BRD9 as a potential therapeutic target.

2019-05-02 | GSE129437 | GEO

Genome-wde mapping of BRD9 binding sites and gene expression changes upon BRD9 knockdown

Project description:Genome-wde mapping of BRD9 binding sites and gene expression changes upon BRD9 knockdown

| PRJNA531322 | ENA

Murine Myoblast C2C12 Cells: Control vs. Mybbp1a Knockdown

Project description:Transcriptional profiling of mouse myoblast cells comparing control vs. Mybbp1a knockdown. Stable clones of C2C12 cells harboring control or Mybbp1a-targeting shRNA were established and further pooled for analysis. Goal was to determine, based on the effects of Mybbp1a depletion on global gene expression, candidate downstream target genes of Mybbp1a, a putative transcriptional co-repressor. Two-condition experiment, control vs. Mybbp1a knockdown C2C12 cells (mixed stable clones). Biological replicates: 2.

2011-08-09 | E-GEOD-31319 | biostudies-arrayexpress

Murine Myoblast C2C12 Cells: Control vs. Mybbp1a Knockdown

2011-08-10 | GSE31319 | GEO

Impact of HypERrlnc Knockdown on the human pericyte transcriptome

Project description:Impact of HypERrlnc Knockdown on the human pericyte transcriptome

| PRJNA358751 | ENA

The role of GABPA,GPD1L and BRD9 in renal cancer progression and metasasis

Project description:RNAseq was performed on the cells with GABPA knockdown, the cells with GPD1L knockdown, the cells with BRD9 knockdown and the control cells.

2022-05-18 | GSE165728 | GEO

BRD9 regulates leukemic cell survival via STAT5 pathway inhibition

Project description:Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer stem cells, which are unable to differentiate. While genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Here, we identify bromodomain-containing protein 9 (BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells including ex vivo primary blasts compared to CD34+. By targeting BRD9 expression in AML, we observed an alteration in proliferation and survival, ultimately resulting in the induction of apoptosis. Intriguingly, genome-wide profiling revealed that BRD9 binds enhancer regions in a cell type-specific manner, regulating cell type-related processes. We unveil a novel BRD9-sustained STAT5 pathway activation via regulation of SOC3 expression levels. Our findings identify a previously undescribed BRD9-STAT5 axis as critical for leukemia maintenance, suggesting BRD9 as a potential therapeutic target.

2019-11-11 | PXD013245 | Pride

Interactome of a TurboID-tagged BRD9 in the presence or absence of IFN-a2

Project description:BRD9 was identified in a genome-wide screen for genes regulating the response to interferon (IFN) in a A549 based reporter cell line. Subsequent experiments determined an involvement of BRD9 in the transcriptional regulation of Interferon-stimulated genes (ISGs) expression following stimulation with IFN-a2. The aim of this proximity-labelling experiments was to gain a more mechanistic understanding of BRD9 recruitment during the IFN signal transduction using A549 cells stably transduced with BRD9-TurboID and mCherry-TurboID fusion proteins. The BRD9 interactome in the absence of IFN- a2 was determined. We found that following IFN-a2 treatment, STAT2 significantly associates with BRD9-TurboID.

2021-08-17 | PXD026926 | Pride

Assessing the Impact of STX4 Knockdown on the Transcriptome of Brown Adipose Tissue

Project description:Assessing the Impact of STX4 Knockdown on the Transcriptome of Brown Adipose Tissue

| PRJNA1045675 | ENA